Rate Video

EHA 2020 | KRT‑232: first-in-class MDM2I for myelofibrosis R/R to JAK inhibitor therapy

Haifa Kathrin Al-Ali

EHA 2020

Myelofibrosis Myeloproliferative Neoplasms Navtemadlin Ruxolitinib

Haifa Kathrin Al-Ali, MD, University Hospital of Halle, Halle, Germany, discusses KRT‑232, a murine double minute 2 inhibitor (MDM2I), for myelofibrosis relapsed or refractory (R/R) to Janus‑associated kinase (JAK) inhibitor treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

The application of JAK inhibitors in the treatment of polycythemia vera and myelofibrosis

Haifa Kathrin Al-Ali • 9 Jun 2016

How to manage myelofibrosis patients on momelotinib who develop peripheral neuropathy

Haifa Kathrin Al-Ali • 10 Jun 2016

What is the unmet medical need of patients with PV and ET?

Haifa Kathrin Al-Ali • 9 Jun 2016

Safety of treating myelofibrosis with ruxolitinib – results from JUMP trial

Haifa Kathrin Al-Ali • 1 Dec 2016

Related Videos

Allo-HSCT in BCR-ABL-negative MPN pretreated with JAK inhibitors

Key updates in MPNs from ASH 2018

Claire Harrison

Rapid responses with targeted agent in Phase I trial for systemic mastocytosis

Daniel DeAngelo

LCL161 for primary myelofibrosis: a new therapy in the field

Naveen Pemmaraju